ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2153 entries already.
A rapid antigen test provides a fast and reliable indication of the presence of the SARS-CoV-2 virus, the causative agent of Covid-19. A positive result of an antigen test is reliable, whereas a negative result does not completely rule out infection with the SARS-CoV-2 virus. The success of rapid tests is therefore limited by the sensitivity of the antibodies used.
Ribbon Biolabs has cashed in €18m in Series A financing led by Hadean Ventures
German mRNA and LNP specialist Ethris GmbH has closed a $26m Series B round led by Laureus Capital.
Evotec SE will use its PanOmics platform to validate and screen targets and drug candidates in ophtalmology for Boehringer Ingelheim.
Pfizer Inc and BioNTech SE have started clinical safety testing of an Omikron-specific vaccine in healthy adults 18 through 55 years of age.
Norway’s immuno-oncology specialist Cytovation A/S has raised $20m in a Series A financing led by early-stage investor Sandwater.
French-Austrian vaccine specialist Valneva SE has demonstrated that its COVID-19 vaccine induced neutralisation of 87% of the Omicron variant.
Leading the way with the industry’s largest portfolio of CE-IVD labeled flow cytometry reagents in the market, Beckman Coulter Life Sciences announces that it has received a EU Quality Management System Certificate under the new In Vitro Diagnostic Medical Devices Regulation (IVDR) for more than 200 flow cytometry reagents developed and manufactured at their Marseille, France facility.
Swiss Neurimmune AG has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical Co., Ltd. covering antibody drug targeting neurodegenerative diseases
German Evotec SE has entered into a US$1bn drug discovery and development partnership with Eli Lilly and Company in the field of metabolic and renal diseases and diabetes.